MannKind Corporation (MNKD) - Product Pipeline Analysis

MannKind Corporation (MNKD) - Product Pipeline Analysis

Summary

MannKind Corporation (MannKind) is a developmental stage biopharmaceutical company, which is engaged in the discovery, development and commercialization of therapeutic products to treat diseases such as diabetes and cancer. The company’s product pipeline includes AFREZZA, the Technosphere Insulin System used for the treatment of diabetes; MKC1106-PP, which is in Phase I clinical trial, intended for the treatment of various solid-tumor cancers and melanoma. The company is preparing to carry out Phase II clinical trials of MKC1106-MT, in the treatment of advanced melanoma. The company's pipeline products also include MKC204, which has the potential to treat certain malignancies and inflammatory diseases. The company’s operations span the US, Europe and Latin America. MannKind is headquartered in California, the US.

This report is a source for data, analysis and actionable intelligence on the MannKind Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize. SHOW LESS READ MORE >

List of Tables
List of Figures
MannKind Corporation - Business Description
Key Facts
MannKind Corporation - Major Products and Services
MannKind Corporation Pipeline Products by Equipment Type
MannKind Corporation Pipeline Products by Development Stage
MannKind Corporation Pipeline Products by Therapy Area
MannKind Corporation Pipeline Products by Trial Phase
MannKind Corporation Pipeline Products by Milestone Summary
AFREZZA - Gen2 Inhaler
Product Status
Product Description
Product Milestone
Product Patent Details
AFREZZA - Medtone Inhaler
Product Status
Product Description
Product Milestone
AFREZZA - Medtone Inhaler Clinical Trial
Product Patent Details
Dreamboat
Product Status
Product Description
Product Milestone
Product Patent Details
MannKind Corporation - Key Competitors
MannKind Corporation - Key Employees
MannKind Corporation - Key Employee Biographies
MannKind Corporation - Locations And Subsidiaries
Head Office
Recent Developments
Aug 04, 2011: MannKind Reports Q2 2011 Results
May 09, 2011: MannKind Reports Net Loss Of $41.5m For Q1 2011
Apr 13, 2011: MannKind’s End-Of-Review Meeting With FDA Rescheduled
Apr 08, 2011: MannKind Provides Regulatory Update
Apr 08, 2011: MannKind Provides Regulatory Update
Feb 10, 2011: MannKind Reports Net Loss Of $38.3m For Q4 2010
Feb 02, 2011: Law Offices Of Howard G Smith Announces Class Action Lawsuit Against MannKind
Oct 29, 2010: MannKind Reports Net Loss Of $45.3 Million For Q3 2010
Aug 23, 2010: MannKind Corporation To Supply AFREZZA To Juvenile Diabetes Research Foundation For Artificial Pancreas Project
Aug 02, 2010: MannKind Reports Net Loss Of $42.2 Million For Q2 2010
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
MannKind Corporation, Key Facts
MannKind Corporation Key Pipeline Products by Equipment Type
MannKind Corporation Key Pipeline Products by Therapy Area
MannKind Corporation Key Pipeline Products by Development Stage
MannKind Corporation Key Pipeline Products by Trial Phase
MannKind Corporation, Key Facts
MannKind Corporation, Major Products and Services
MannKind Corporation Number of Pipeline Products by Equipment Type
MannKind Corporation Pipeline Products by Equipment Type
MannKind Corporation Number of Pipeline Products by Development Stage
MannKind Corporation Pipeline Products by Development Stage
MannKind Corporation Number of Pipeline Products by Therapy Area
MannKind Corporation Pipeline Products by Therapy Area
MannKind Corporation Number of Pipeline Products by Trial Phase
MannKind Corporation Pipeline Products by Trial Phase
MannKind Corporation Number of Pipeline Products By Milestone Summary
MannKind Corporation Pipeline Products by Milestone Summary
AFREZZA - Gen2 Inhaler - Product Status
AFREZZA - Gen2 Inhaler - Product Description
AFREZZA - Gen2 Inhaler - Product Milestone
AFREZZA - Gen2 Inhaler - Patent Details
AFREZZA - Medtone Inhaler - Product Status
AFREZZA - Medtone Inhaler - Product Description
AFREZZA - Medtone Inhaler - Product Milestone
AFREZZA - Medtone Inhaler - A Phase 1, Open-Label Study To Investigate The Effect Of Albuterol (Salbutamol) And Fluticasone On The Pharmacokinetics Of Inhaled Technosphere Insulin Inhalation Powder In Healthy Subjects
AFREZZA - Medtone Inhaler - A Phase 1, Open-Label, Controlled Clinical Trial To Evaluate Pharmacokinetics After Administration Of Technosphere Insulin Inhalation Powder Alone And With Salbutamol (Albuterol) And/Or After Methacholine Challenge Testing In Subjects With Asthma Versus Matched Healthy Subjects Without Asthma
AFREZZA - Medtone Inhaler - A Phase3, Multi-Center, Open-Label, Randomized, Clinical Trial Evaluating The Efficacy And Safety Of Technosphere Insulin Inhalation Powder In Combination With Lantus Versus Humalog In Combination With Lantus In Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period
AFREZZA - Medtone Inhaler - A Phase 2, Open-Label, Randomized, 2-Way Crossover, Clinical Trial To Compare The Pharmacokinetics Of 2 Formulations of "Intended Commercial Product" Technosphere Insulin Inhalation Powder And To Determine The Bioavailability Of A 30 Unit Cartridge of "Intended Commercial Product" Technosphere Insulin Inhalation Powder Versus A 10 Unit Subcutaneous Injection Of Insulin Lispro In Subjects With Type 1 Diabetes Mellitus
AFREZZA - Medtone Inhaler - A Phase 3, 12-Month Treatment, Multicenter, Randomized, Open-Label, Parallel Group Clinical Trial Comparing Prandial Subcutaneous Insulin With Prandial Inhaled Technosphere Insulin In Subjects With Diabetes Mellitus And Asthma
AFREZZA - Medtone Inhaler - A Phase 2 Randomized, Open Label, Multi-Center Study Of The Use Of Prandial Inhaled Technosphere Insulin In Combination With Basal Subcutaneous Lantus As Basal Insulin Versus Prandial Subcutaneous NovoRapid In Combination With Basal Subcutaneous Lantus Insulin In Subjects With Type 1 Diabetes Mellitus
AFREZZA - Medtone Inhaler - A Phase 2, Single-Center, Open-Label, Pharmacodynamic Clinical Trial To Evaluate The Effect Of Technosphere Insulin Inhalation Powder On Postprandial Glucose Levels In Subjects With Type 1 And Type 2 Diabetes Mellitus Ingesting Meals With Varied Carbohydrate Content
AFREZZA - Medtone Inhaler - Efficacy And Safety Of Inhaled Technosphere Insulin Compared To Technosphere Placebo In Patients With Type 2 Diabetes Mellitus Following Diabetes Education
AFREZZA - Medtone Inhaler - Evaluation Of Intrapatient Variability In Bioavailability Of Technosphere Insulin Compared With Subcutaneous Regular Human Insulin In Patients With Type 2 Diabetes
AFREZZA - Medtone Inhaler - A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing The Efficacy And Safety Of Prandial Inhalation Of Technosphere/Insulin In Combination With Metformin Or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and a Secretagogue) In Subjects With Type 2 Diabetes Mellitus Sub-Optimally Controlled On Combination Metformin And A Secretagogue.
AFREZZA - Medtone Inhaler - Evaluation Of The Effect Of Symptomatic Upper Respiratory Infections On Pharmacological Characteristics Of TechnosphereÒ/Insulin In Subjects With Diabetes Mellitus After A Meal Challenge
AFREZZA - Medtone Inhaler - A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing The Efficacy And Safety In Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin And Prandial Inhalation Of Technosphere/Insulin Versus Subcutaneous Basal And Prandial Insulin Over A 52-Week Treatment Period And A 4-Week Follow Up
AFREZZA - Medtone Inhaler - Pulmonary Outcomes Within a 2-Year Period In Subjects With Diabetes Mellitus Treated With Technosphere /Insulin Or Usual Antidiabetic Treatment And In Subjects Without Abnormalities In Glucose Control.
AFREZZA - Medtone Inhaler - A Phase 3 Randomized, Open Label, Multi-Center Comparative Study Of Technosphere /Insulin Versus Rapid Acting Insulin In Subjects With Type-2 Diabetes Mellitus Receiving Lantus As Basal Insulin
AFREZZA - Medtone Inhaler - A Randomized, Double-Blind, Controlled, Stepwise Titration Study To Evaulate Dose Response To Prandial Administration Of Inhaled Technosphere/Insulin Or Technosphere In Patients With Type 2 Diabetes Mellitus Who Are Sub-Optimally Treated
AFREZZA - Medtone Inhaler - A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing The Efficacy And Safety In Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin And Prandial Inhalation Of Technosphere /Insulin Versus Subcutaneous Premixed Insulin Therapy Over A 52-Week Treatment Period And A 4-Week Follow-up
AFREZZA - Medtone Inhaler - To Compare The Effect Of Inhaled Insulin With Subcutaneously Injected Insulin In Subjects With Type 2 Diabetes Mellitus.
AFREZZA - Medtone Inhaler - A Three-Year, Safety And Tolerability, Open-Label, 'Follow On' Trial Evaluating Technosphere /Insulin in Subjects With Type 2 Diabetes Mellitus.
AFREZZA - Medtone Inhaler - A Parallel, Controlled, Multi-Center, Single-Dose, One-Period Euglycemic Clamp Study Comparing Prandial Inhalation of Technosphere Insulin in Smokers and Non-Smokers With Type 2 Diabetes
AFREZZA - Medtone Inhaler - Patent Details
Dreamboat - Product Status
Dreamboat - Product Description
Dreamboat - Product Milestone
Dreamboat - Patent Details
MannKind Corporation, Key Employees
MannKind Corporation, Key Employee Biographies

List of Figures
MannKind Corporation Key Pipeline Products by Equipment Type
MannKind Corporation Pipeline Products by Equipment Type
MannKind Corporation Pipeline Products by Development Stage
MannKind Corporation Pipeline Products by Therapy Area
MannKind Corporation Pipeline Products by Trial Phase
MannKind Corporation Pipeline Products by Milestone Summary

Pfizer Inc.
Eli Lilly and Company
Emisphere Technologies, Inc.
GlaxoSmithKline plc
Novo Nordisk A/S